Renaissance Technologies LLC Has $361,000 Stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

Renaissance Technologies LLC lifted its position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) by 57.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 136,773 shares of the company’s stock after acquiring an additional 49,704 shares during the quarter. Renaissance Technologies LLC owned approximately 0.55% of Eledon Pharmaceuticals worth $361,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ELDN. Vanguard Group Inc. grew its position in shares of Eledon Pharmaceuticals by 39.4% during the 1st quarter. Vanguard Group Inc. now owns 969,121 shares of the company’s stock worth $1,996,000 after buying an additional 273,703 shares during the period. Marco Investment Management LLC raised its stake in shares of Eledon Pharmaceuticals by 22.3% during the 2nd quarter. Marco Investment Management LLC now owns 30,344 shares of the company’s stock worth $80,000 after purchasing an additional 5,535 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of Eledon Pharmaceuticals during the 2nd quarter valued at approximately $80,000. Finally, CM Management LLC increased its position in Eledon Pharmaceuticals by 14.3% in the first quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $330,000 after buying an additional 20,000 shares during the last quarter. 56.77% of the stock is owned by institutional investors.

Eledon Pharmaceuticals Trading Down 0.4 %

Eledon Pharmaceuticals stock opened at $2.68 on Friday. Eledon Pharmaceuticals, Inc. has a 1-year low of $1.07 and a 1-year high of $3.35. The firm has a market capitalization of $106.29 million, a price-to-earnings ratio of -1.31 and a beta of 0.88. The firm has a 50 day simple moving average of $2.65 and a 200 day simple moving average of $2.53.

Eledon Pharmaceuticals (NASDAQ:ELDN) last released its quarterly earnings data on Monday, August 19th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.01). On average, equities research analysts forecast that Eledon Pharmaceuticals, Inc. will post -1.52 EPS for the current year.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).